-
Intravacc licences CimCure’s iBoost vaccine technology
pharmaceutical-technology.
July 03, 2020
Dutch research and development vaccine institute Intravacc has collaborated with cancer immunotherapies developer CimCure to in-licence the latter’s iBoost technology for vaccines.
-
Dutch Intravacc to in-license CimCure’s iBoost technology, expands its vaccine platform portfolio
expresspharma
July 02, 2020
The iBoost (immune boost) technology was developed at Amsterdam UMC, lab-location VUMC, by Prof. Dr. Arjan Griffioen, professor of experimental oncology and CSO at CimCure.
-
Intravacc’s experimental whooping cough vaccine shows promising results in a preclinical study
expresspharma
June 23, 2020
The study shows that intranasal immunization induced both excellent systemic and local immune responses, but also prevented colonization of the lung, trachea and nose.
-
Intravacc and Versatope to develop universal influenza vaccine based on OMV technology
expresspharma
June 09, 2020
According to Centers for Disease Control and Prevention, influenza vaccines were overall 29 per cent effective during the 2018–2019 influenza season due to the emergence of new, late season viral strains.
-
Intravacc forms alliance to develop intranasal Covid-19 vaccine
pharmaceutical-technology
June 08, 2020
Dutch research and development vaccine institute Intravacc has collaborated with Wageningen Bioveterinary Research (WBVR) and Utrecht University to develop an intranasal vaccine against Covid-19.
-
Intravacc and EpiVax to develop Covid-19 vaccine candidate
pharmaceutical-technology
June 04, 2020
Dutch research and development vaccine institute Intravacc has partnered with US-based biotechnology firm EpiVax to advance a Covid-19 vaccine candidate.
-
Serum Institute of India and Intravacc to develop Bioneedles
financialexpress
June 01, 2018
(L-R) Bruno Bruins, Dutch Minister for Medical Care and Sports,Mark Rutte, Prime Minister of the Netherlands,Thijs Veerman, CEO, Intravacc,Dr Suresh Jadhav